In this review, we present the ABC Pathway for the holistic, integrated management of patients diagnosed with AF: "A" avoid stroke with anticoagulation; "B" for better symptom management with patient-centered, symptom directed decisions on rate or rhythm control; and "C" cardiovascular and comorbidity risk reduction, including lifestyle factors and psychological morbidity.
The ABC-stroke and ABC-bleeding scores evaluated in this anticoagulated clinical trial cohort were well calibrated and outperformed the CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED scores, respectively.
Using animal models, our data show that removal of plasticity-inhibiting signals in the spinal cord (via intraspinal injections of the enzyme chondroitinase ABC) augments rewiring of circuits connecting the brain to the spinal cord, even weeks after stroke.
Our aim was to investigate the short-term variability of the cardiac biomarkers and evaluate whether the ABCstroke risk score provides a stable short-term risk estimate.